Netilmicin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Netilmicin.svg | |
| Netilmicin
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | J01 S01AA23 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H41N5O7 |
| Mol. mass | 475.58 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 2.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Netilmicin | |
|
Articles | |
|---|---|
|
Most recent articles on Netilmicin | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Netilmicin at Clinical Trials.gov Clinical Trials on Netilmicin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Netilmicin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Netilmicin Discussion groups on Netilmicin Patient Handouts on Netilmicin Directions to Hospitals Treating Netilmicin Risk calculators and risk factors for Netilmicin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Netilmicin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Netilmicin is a member of the aminoglycoside family of antibiotics. These antibiotics have the ability to kill a wide variety of bacteria. Netilmicin is not absorbed from the gut and is therefore only given by injection or infusion. It is only used in the treatment of serious infections particularly those resistant to gentamicin.
Available dosage forms include: US: netilmicin sulfate injection 100 mg/mL (Vials of 2 mL and pharmacy bulk vials of 20 mL) & 50 mg/mL (Vials of 2 mL) UK: netilmicin (as Sulphate): 10mg/ml (1.5 ml amp), 50mg/ml (1-ml amp), 100mg/ml(1-ml,1.5-ml & 2-ml amp) France: Nétilmicin sulfate: Amp 25mg/1ml, 50 mg/2ml, 100 mg/1ml, 150mg/1,5 ml
Ingredients for 100 mg/ml vial
Netilmicin (as sulphate)………100 mg Sodium metabisulfite……………2.4 mg Sodium sulfite……………………..0.8 mg Edetate disodium………………..0.1 mg Benzyl alcohol…………………...10 mg Water for injection……………qs 1 ml
FDA approval date: February 28, 1983
Comparison with drugs of the same therapeutic category
According to the British National Formulary (BNF), netilmicin has similar activity to gentamicin, but less ototoxicity in those needing treatment for longer than 10 days.Netilmicin is active against a number of gentamicin-resistant Gram-negative bacilli but is less active against Ps. Aeuroginosa than gentamicin or tobramycin.
However according to the below-mentioned studies, the above advantages are somehow controversial:
Netilmicin (Netromycin, Schering-Plough): In summary, netilmicin has not been demonstrated to have significant advantages over other aminoglycosides (Gentamicin,Tobramicin,Amikacin), and it is more expensive; thus, its potential value is limited. Drug Intelligence & Clinical Pharmacy: Vol. 17, No. 2, pp. 83-91.
Once-daily gentamicin versus once-daily netilmicin in patients with serious infections—a randomized clinical trial: We conclude that with once-daily dosing no benefit of netilmicin over gentamicin regarding nephro- or ototoxicity could be demonstrated. Journal of Antimicrobial Chemotherapy (1994) 33, 823-835.
Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial: We conclude that with once-daily treatment no benefit of netilmicin over gentamicin regarding nephro- or ototoxicity could be demonstrated. Clin Otolaryngol Allied Sci. 1995 Apr;20(2):118-23.
Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients: We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin. Arch Intern Med. 1986 Dec;146(12):2329-34.
Daily single-dose aminoglycoside administration. Therapeutic and economic benefits : Animal studies have shown that dosing aminoglycosides once daily is more efficient and less nephrotoxic than the conventional multiple daily dosing regimens. Netilmicin and amikacin are the drugs most often used in clinical trials of once-daily dosing regimens. Ugeskr Laeger. 1993 May 10;155(19):1436-41.
Comparison of Netilmicin with Gentamicin in the Therapy of Experimental Escherichia coli Meningitis: Because of its reduced toxicity and greater in vivo bactericidal activity, netilmicin may offer an advantage over gentamicin in the therapy of gram-negative bacillary meningitis. Antimicrob Agents Chemother. 1978 June; 13(6): 899-904.
A comparison of netilmicin and gentamicin in the treatment of pelvic infections: The microbacteria isolated by standard culture techniques before therapy revealed Neisseria gonorrhoeae in 69% and 51% of the netilmicin and gentamicin groups, respectively; anaerobic organisms were cultured in about 75% of each group. Obstetrics & Gynecology 1979;54:554-557.
Netilmicin: a review of toxicity in laboratory animals: Presently available data suggest that netilmicin offers distinct advantages over older aminoglycosides. Final conclusions must await prospective randomized double-blind trials in man. J Int Med Res. 1978;6(4):286-99.
Nonparallel nephrotoxicity dose-response curves of aminoglycosides: Nephrotoxicity comparisons of aminoglycosides in rats, utilizing large multiples of human doses, have indicated an advantage for netilmicin. However, no nephrotoxicity advantage of netilmicin has been demonstrated at the lower doses used in clinics. Antimicrob Agents Chemother. 1981 June; 19(6): 1024–1028.
Comparative ototoxicity of netilmicin, gentamicin, and tobramycin in cats: Under the conditions of this study, at least a twofold (vestibular) to fourfold (cochlear) relative safety margin for ototoxicity was established in favor of netilmicin over tobramycin and gentamicin. Toxicol Appl Pharmacol. 1985 Mar 15;77(3):479-89.
Comparison of Netilmicin and Gentamicin Pharmacokinetics in Humans: In a crossover study, single doses of netilmicin and gentamicin were administered intramuscularly, each at 1.0 and 2.5 mg/kg. No significant differences were observed between the two drugs in disposition half-life, rate of distribution and elimination, area under the serum concentration-time curve, urinary excretion, total body clearance, and renal clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1980, p. 184-187. Schering-Plough Research Division, Bloomfield, New Jersey 07003.
External links
- Hemsworth S, Nunn A, Selwood K, Osborne C, Jones A, Pizer B (2005). "Once-daily netilmicin for neutropenic pyrexia in paediatric oncology.". Acta Paediatr 94 (3): 268-74. PMID 16028643.
- Klingenberg C, Småbrekke L, Lier T, Flaegstad T (2004). "Validation of a simplified netilmicin dosage regimen in infants.". Scand J Infect Dis 36 (6-7): 474-9. PMID 15307571.
- Brooks J, Marlow N, Reeves B, Millar M (2004). "Use of once-daily netilmicin to treat infants with suspected sepsis in a neonatal intensive care unit.". Biol Neonate 86 (3): 170-5. PMID 15237240.
Antibacterials for systemic use: aminoglycosides (J01G) | |
|---|---|
| -mycin (Streptomyces) | Streptomycin • Neomycin (Framycetin, Paromomycin, Ribostamycin) • Kanamycin (Amikacin, Dibekacin, Tobramycin) • Hygromycin B • Spectinomycin |
| -micin (Micromonospora) | Gentamicin (Netilmicin, Sisomicin, Isepamicin) • Verdamicin |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
